ArticleResearch square2025
Development of an atrazine immunoassay based on highly catalytically active Au@PtNPs and specific nanobody.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
9 authors.
Funding
Abstract
Atrazine, one of the mostly used herbicides globally, is characterized as long residual effects on sensitive crops such as wheat, soybeans, and sweet potatoes. Also, its prolonged residues in the environment can jeopardize the health of non-target organisms and the safety of environmental ecosystems. Therefore, it is important to develop efficient and sensitive methods to detect trace atrazine in the environment. In this study, the nanobodies specifically recognizing atrazine were successfully obtained through immunize alpaca and phage display libraries, and an indirect competitive immunoassay (ic-ELISA) based on nanobodies was constructed with an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.